anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/AIMS: Colorectal cancer (CRC) is one of the deadliest cancers worldwide, mostly arising from adenomatous polyps. Mounting evidence has demonstrated that changes in the gut microbiome play key roles in CRC progression, while quite few studies focused on the altered microbiota architecture of advanced adenoma (AA), a crucial precancerous stage of CRC. Thus, we aimed to investigate the microbial profiles of AA patients.
MATERIALS AND METHODS: Fecal samples were collected from 26 AA patients and 26 age- and sex-matched normal controls (NC), and analyzed by shotgun metagenomic sequencing.
RESULTS: Gut microbial dysbiosis was observed in AA patients with lower alpha diversity. Advanced adenoma was characterized by an increased Bacillota/Bacteroidota ratio and higher Pseudomonadota levels compared to normal individuals. Linear discriminant analysis effect size (LEfSe) analysis was performed and identified 14 microbiota with significantly different abundance levels between AA and NC groups. Functional analysis revealed that tryptophan metabolism was upregulated in AA. Correspondingly, the expressions of gut microbes implicated in tryptophan metabolism also changed, including Akkermansia muciniphila, Bacteroides ovatus, Clostridium sporogenes, and Limosilactobacillus reuteri. The microbial network suggested that AA exhibited decreased correlation complexity, with Escherichia coli and Enterobacteriaceae unclassified harboring the strongest connectivity. A diagnostic model consisting of 3 microbial species was established based on random forest, yielding an area under the curve (AUC) of 0.799.
CONCLUSION: Our study profiled the alterations of the gut microbiome in AA patients, which may enrich the knowledge of microbial signatures along with colorectal tumorigenesis and provide promising biomarkers for AA diagnosis.
BACKGROUND: Urinary incontinence (UI) is common among postpartum women, but many do not seek medical help due to limited knowledge. Understanding the level of knowledge about UI in this population is essential for improving care-seeking behaviors and implementing targeted interventions.
OBJECTIVE: The objective was to examine knowledge regarding UI among postpartum women with UI within 6 weeks to 1 year after delivery.
METHODS: A cross-sectional study was conducted at obstetric clinic in two level-three grade A hospitals in Shenzhen, China, from January 2023 to June 2023. Women in their 6 weeks to 1 year after delivery with UI were asked to complete a questionnaire comprising three sections: (1) demographic variable; (2) International Consultation on Incontinence Questionnaire Short Form (ICIQ-UI SF); and (3) The Urinary Incontinence Quiz (UIQ).
RESULTS: A total of 1228 women completed the questionnaire. Their mean UIQ score was 6.63 ± 3.51 (minimum = 2, maximum = 15), indicating the deficiency of UI knowledge among Chinese postpartum women. A total of 86.4% of participants experienced slight or moderate postpartum UI. The results of multivariate linear regression models for UIQ reveal significant independent associations between questionnaire scores and two variables: experience in pelvic floor muscle training (PFMT) (p < 0.001) and UI treatment in the past (p < 0.001). The overall model fit was R2 = 0.559 (p < 0.001). The regression coefficients for the experience in PFMT and UI treatment in the past were 2.301 and 4.916, respectively. However, no other discernible factors were identified to distinguish between those with and without adequate knowledge.
CONCLUSIONS: Postpartum women with UI within 6 weeks to 1 year after delivery had poor knowledge of UI. Targeted educational interventions focusing on PFMT and early treatment for UI are essential.
The present invention relates to a traditional Chinese medicine for treating colpitis and cervicitis, which is prepared from lightyellow sophora root, common cnidium fruit, rhubarb, stemona root, smoked plum, borax, borneol, alum and liquorice. The medicine is prepared into medicine forms of capsules, effervescent tablets, cleansing solutions, gel, suppository, etc. by conventional methods of the traditional Chinese medicines. The efficacy of the medicines in the prescription generates synergistic effect, and thereby, the medicine can effectively treat colpitis, cervicitis, etc. The medicine of the present invention does not contain western medicine components, is a pure traditional Chinese medicine and has the efficacy of clearing away heat, drying dampness, resisting bacteria, relieving inflammation, killing insects and relieving itch. The medicine of the present invention is mainly used for treating woman leukorrhea damp-heat and downward pouring and has the advantages of obvious treatment effect, less side effect, no traumatic occlusion. In addition, the medicine has the action of improving low female sexual functions caused by gynecopathy and can treat dermatophytosis and hemorrhoid.
Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
The invention relates to a solid composition administrated through nose, comprising volatile active ingredient and matrix, wherein the volatile active ingredient is uniformly mixed with the matrix. The invention also relates to a preparation method and nasal administration device thereof. The nasal administration device comprises two kits (1) for housing all the solid composition and an elastic nasal clip (2) for connecting the two kits (1) and the shape of the kit (1) adapts to the nose cavity shape and at least one air hole (11) is opened on the kit (1). The solid composition is housed in the kit (1) and the kit (1) is placed in the nasal cavity (4), and the elastic nasal clip (2) clips the nasal septum (3), and then the volatile component enters into the lungs along with the breath after evaporating, finally enters into the blood to play a therapeutic effect. The device can be easily administered, rapidly take effects, thereby avoiding unnecessary extension after onset. The solid composition is free from injection or oral administration and has simple production technique compared with aerosol in need of propellant and pressure vessel.
Atopic dermatitis and psoriasis are common chronic inflammatory diseases of high incidence that share some clinical features, including symptoms of pruritus and pain, scaly lesions, and histologically, acanthosis and hyperkeratosis. Meanwhile, they are both commonly comorbid with metabolic disorders such as obesity and diabetes, indicating that both diseases may exist with significant metabolic disturbances. Metabolomics reveals that both atopic dermatitis and psoriasis have abnormalities in a variety of metabolites, including lipids, amino acids, and glucose. Meanwhile, recent studies have highlighted the importance of the microbiome and its metabolites in the pathogenesis of atopic dermatitis and psoriasis. Metabolic alterations and microbiome dysbiosis can also affect the immune, inflammatory, and epidermal barrier, thereby influencing the development of atopic dermatitis and psoriasis. Focusing on the metabolic and microbiome levels, this review is devoted to elaborating the similarities and differences between atopic dermatitis and psoriasis, thus providing insights into the intricate relationship between both conditions.
The invention provides a method for separating a polyphenolic compound such as resveratrol from biomass. The method comprises feeding the biomass into an aqueous two-phase system with a polymer phase and a salt phase and separating the polymer phase which includes the polyphenolic compound from the salt phase. The polymer may be a polyether. The salt may be a tartrate salt, a citrate salt, a carbonate salt, a phosphate salt or a sulphate salt. The biomass may be derived from grape vines, knotweeds, pine trees, peanut plants, cocoa bushes,  Vaccinium  shrubs; geraniums of the  Pelargonium  genus, or the herb  Polygonum Cuspidatum , for example. The biomass may be derived from winery waste. The polymer phase may comprise 10% (w/w) polyethylene glycol with a molecular weight of 8000 g/mol. The salt phase may comprise 15% (w/w) tartrate salt. The invention extends to medicaments and dietary supplements which include the polyphenolic compound.
The wound was filled with black foam (Granufoam®, KCI) and covered with plastic folio. A continuous pressure of 125 mmHg was applied using the hospital suction system. The dressing changes were performed every 48 hours.
INTRODUCTION: Congenital/early-onset sensorineural hearing loss (SNHL) is one of the most common hereditary disorders in our environment. There is increasing awareness of the importance of an etiologic diagnosis, and genetic testing with next-generation sequencing (NGS) has the highest diagnostic yield. Our study shows the genetic results obtained in a cohort of patients with bilateral congenital/early-onset SNHL.
MATERIALS AND METHODS: We included 105 children with bilateral SNHL that received genetic testing between 2019 and 2022. Genetic tests were performed with whole exome sequencing, analyzing genes related to hearing loss (virtual panel with 244 genes).
RESULTS: 48% (50/105) of patients were genetically diagnosed. We identified pathogenic and likely pathogenic variants in 26 different genes, and the most frequently mutated genes were GJB2, USH2A and STRC. 52% (26/50) of variants identified produced non-syndromic hearing loss, 40% (20/50) produced syndromic hearing loss, and the resting 8% (4/50) could produce both non-syndromic and syndromic hearing loss.
CONCLUSIONS: Genetic testing plays a vital role in the etiologic diagnosis of bilateral SNHL. Our cohort shows that genetic testing with NGS has a high diagnostic yield and can provide useful information for the clinical workup of patients.
Since 2004, group exercise sessions have been organized as a routine form of treatment for individuals diagnosed with rheumatism in the Department of Physiotherapy and Rehabilitation of Hacettepe University. The first evaluation will be made if the individuals who come to the routine doctor's examination agree to participate in the study. According to being included in one of the two groups as those who decided to attend the BETY sessions that have been going on for 18 years and those who did not agree to attend the sessions; The individuals included in the BETY group (Group 1) will be evaluated on the day of the last exercise session after their participation in the 12-week exercise group.
The invention relates to a method for lowering organochlorine content in Ginseng extract, belonging to the field of modernization of traditional Chinese medicine. The invention solves the problem that the organochlorine content in the Ginseng extract is too high. The invention is characterized in that fresh Ginseng is soaked with calcium hypochlorite aqueous solution; then using ethanol as extraction solvent to backflow and extract to obtain Ginseng extract; adding activated carbon into the Ginseng extract to carry out agitation and adsorption; then carrying out natural precipitation, using an activated carbon filtering machine to filter the precipitated supernatant liquid to obtain the Ginseng extract having gone through the stripping process. The invention has the advantages that the calcium hypochlorite is used to oxidize and degrade poisonous pesticide macromolecules into nontoxic micromolecule organic matter prone to be dissolved in water without causing secondary pollution when being used; the activated carbon is agitated to further adsorb organochlorine residue. With the adopted method of the invention, the residue is lower than the national limitation standard and content of ginsenoside in the extract is not affected. The method of the invention is used to lower the organochlorine content in the Ginseng extract.
The invention relates to blood-tonifying beauty treatment wine. An ingredient medicine is prepared by mixing 20 parts of radix astragali, 25 parts of Chinese angelica, 15 parts of barbary wolfberry fruit, 10 parts of rose, and 35 parts of red dates. The ingredient medicine is fried by slow fire, dried by airing and ground to ingredient medicine powder. The ingredient medicine powder is added with 1000 ml of pure grain-made original liquor, sealed in the container, and shocked once daily and soaked for 7-8 days, thus the blood-tonifying beauty treatment wine is prepared. The blood-tonifying beauty treatment wine is simple in recipe, convenient to drink, and has the effects of tonifying blood, caring beauty and anti-aging. The beauty of women can last by long-term drinking.
A method for detecting the autoimmune reaction in the patient with the ischemic heart disease provides for the analysis of the blood serum sample. In the sample of 0.1 mL, the proteins are precipitated with 0.9 mL of 20% solution of trichloroacetic acid. The equal volume (1 mL) of 0.1 M 2,4-dinitrophenyl hydrazine (2,4-DPH) solution in 2N НСl and ethanol (2,4-DPH is completely dissolved at the boiling bath). The equal volume of 2N НСl is added to the control sample instead of 2,4-DPH. Upon 1-hour incubation at room temperature, the samples are centrifuged at 6,000 g for 15-20 minutes. The pellet is washed thrice with ethanol-ethyl acetate (1:1). The sample is then centrifuged at 6,000 g for 15-20 minutes, and the pellet is dried for removing the rest of the solvent (ethanol-ethyl acetate) and dissolved in 8M solution of urea. The urea solution in a volume of 4 mL is added to the pellet, and the mixture is incubated for 5 minutes at the boiling water until the complete dissolution. The optical density of the samples is measured spectrophotometrically at 370 nm. The values exceeding 6.5 conventional units of density per 1 mL are considered as suggesting the autoimmune reaction.
ZYPREXA RELPREVV is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-,4,4′-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (1:1), monohydrate. The formula is C17H22N4S•C23H14O6•H2O, which corresponds to a molecular weight of 718.8. The chemical structure is:

ZYPREXA RELPREVV is a long-acting form of olanzapine and is intended for deep intramuscular gluteal injection only.

ZYPREXA RELPREVV includes a single-dose vial of the drug product and a vial of the sterile diluent for ZYPREXA RELPREVV.

The drug product is olanzapine pamoate monohydrate, present as a yellow solid in a glass vial equivalent to 210, 300, or 405 mg olanzapine base per vial. The diluent for ZYPREXA RELPREVV is a clear, colorless to slightly yellow solution in a glass vial and is composed of carboxymethylcellulose sodium, mannitol, polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection. The drug product is suspended in the diluent for ZYPREXA RELPREVV to a target concentration of 150 mg olanzapine per mL prior to intramuscular injection.
PURPOSE:To obtain a bathing agent composition, containing an enzyme, sulfite and compound having clathration ability, excellent in enzymic activity and scarcely emitting malodor peculiar to the enzyme even by preservation for a long period with hardly any enzymic smell even in dissolving thereof in bath water after the preservation. CONSTITUTION:A bathing agent composition containing an enzyme, a sulfite and a compound having clathration ability. The enzyme is not especially limited and, e.g. protease and lipase are used. Sodium sulfite, potassium sulfite, magnesium sulfite, sodium bisulfite, etc., are cited as the sulfite and blended in an amount of 0.1-5wt.% based on the composition. beta-Cyclodextrin or methylated beta-cyclodextrin is used as the compound having the clathration ability.
In this multicenter, randomized, double-blind, placebo-controlled trial in patients with coronary heart disease,240 eligible patients aged ≥18 years will be randomized to receive placebo or Xuesaitong Soft Capsules(1.32g/d) and be followed up for 3 months. The primary endpoint of this study is hsCRP change from baseline to 3 months. The secondary endpoint is the changes of following indicators or scores from baseline to 3 months:(Ⅰ)other inflammation indicators except for hsCRP. (Ⅱ) inhibition of platelet aggregation; (Ⅲ)endothelial function indicators; (Ⅳ)blood lipid levels; (Ⅴ) seattle angina questionnaire score; (Ⅵ)36-item short form health survey score. The safety of using Xuesaitong soft capsules in patients with coronary heart disease will also be evaluated. The generalized linear mixed effects model will be used to evaluate the efficacy endpoint for the "full analysis set". For the safety analysis set, Chi-square test will be used to evaluate the safety endpoint.
Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Bipolar Disorder (BD) is a serious medical illness that causes drastic shifts in a person's mood, energy, and ability to function. BD symptoms alternate from increased energy, restlessness, and overly good mood to a lasting sad, anxious, or empty mood and feelings of hopelessness or pessimism. Research suggests that children of parents with BD are at risk for developing mood disorders because of predisposing genetic factors and stressful life events, many of which may be related to their parents' unstable clinical state. Adolescent children of parents with BD must deal simultaneously with the difficult task of negotiating their own developmental transitions, as well as living with a parent with BD. It may be possible to detect symptoms of BD or other mood disorders early in adolescence and prevent the disorder from further interfering with someone's life. This study will develop and refine strategies for early detection and primary prevention of mood disorders and associated impairment in adolescent children of parents with BD.

Participants in this single-blind study will be randomly assigned to receive either interpersonal psychotherapy with adolescents (IPT-PA) or a control intervention, educational clinical monitoring (ECM), for 12 weeks. Participants assigned to IPT-PA will attend twelve sessions. The first four sessions will last 90 minutes each, and will include both family psychoeducation and individual psychotherapy with the adolescent. The remaining sessions will be 45 minutes each, and will include only individual psychotherapy with the adolescent. Participants assigned to ECM will each be assigned to a therapist. During the initial two sessions, which will take place over 2 consecutive weeks, the therapist will focus on mood disorder psychoeducation and participants will receive related written educational material. Participants will then meet with their therapists monthly for 30-minute sessions. Symptoms and functioning will be assessed, but no assistance on building interpersonal skills will be provided. A participant may request a second session each month, but if more than two monthly sessions are required, the participant will be referred for therapy. Mood episodes and symptoms, symptom severity, and functioning will be assessed for all participants at Weeks 6 and 12 and Months 6, 12, and 18 post-treatment.
The approach is to conduct a single ascending dose trial in a controlled human laboratory setting with individuals with a DSM-5 diagnosis of OUD (n=30) actively using illicit fentanyl. After obtaining informed consent and establishing eligibility, 10 participants will be scheduled for an inpatient visit lasting 5 days-4 nights and receive XR-BUP when not yet experiencing any opioid withdrawal. Participants will receive fentanyl to prevent the emergence of withdrawal, and on the following morning, receive XR-BUP 16mg in single-blind fashion. If at least 90% successfully complete induction (success defined as experiencing no precipitated withdrawal) with the 16mg dose, then we will proceed with 10 more participants to receive the 24mg dose. If at least 90% successfully complete induction the 24mg dose, then we will proceed with 10 more participants to the 32mg dose. Timed blood samples will be collected in heparinized Vacutainer tubes via a catheter in the antecubital vein at baseline, and at 0.5, 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours after the XR-BUP injection.
Diabetes, especially type 2, is considered a risk situation for atherosclerotic cardiovascular disease (ASCVD). Subjects with diabetes type 2 have a mortality rate due to ASCVD 3 times higher than that found in the general population, attributed to hyperglycemia and the frequent association of other cardiovascular risk factors, such as atherogenic dyslipidemia. Numerous scientific societies have established a risk classification for ASCVD in diabetes based on 3 degrees (moderate, high and very high). The objectives of dyslipidemia control are clearly defined and accepted, and vary depending on the previously established cardiovascular risk. In moderate or intermediate risk, the guidelines propose a less intensive intervention, maintaining LDL-C levels<100mg/dL and NO-HDL-C levels<130mg/dL, and waiting 10 years until reaching the high-risk category to initiate more intensive treatment. However, during the decade of follow-up recommended in the guidelines, cholesterol deposition in the arterial wall increases, facilitating the development of an unstable and inflammatory atheromatous plaque, and the development of ASCVD. Alternatively, diabetes could be considered from the outset to be a high-risk situation and the goal should be LDL-C<70mg/dL. Furthermore, maintaining LDL-C levels<70mg/dL contributes to reducing and stabilizing atheromatous plaque, avoiding or reducing mortality episodes due to ASCVD during those years of diabetes evolution. Should we maintain the proposed objectives in subjects with diabetes and moderate risk for a decade until reaching the high cardiovascular risk phase or, on the contrary, should we adopt a more intensive stance from the beginning seeking to reduce cardiovascular risk in the majority of patients with diabetes? Is it better to wait or prevent with effective therapeutic measures from the first moment?
Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann \& Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
<P>PROBLEM TO BE SOLVED: To obtain a highly safe and readily producible gel composition optimal when utilized as a base for a cosmetic, a medicine, or the like, having high strengths and good stretchability, stable even in use over a long period, and to provide a method for producing the same.  <P>SOLUTION: The gel composition is obtained by heating a mixture containing natural polysaccharides containing at least uronic acid and a deoxysaccharide in a constituent monosaccharide, a polyhydric alcohol and water and has the stretchability. The method for producing the same is provided. Polysaccharides produced by a microorganism can be used as the natural polysaccharides, e.g. the polysaccharides produced by a bacterium Alcaligenes latus B-16 strain. Acidic polysaccharides containing glucose, fucose, glucuronic acid and rhamnose as constituent monosaccharides can be used as the polysaccharides.  <P>COPYRIGHT: (C)2005,JPO&NCIPI